Andrew X Zhu

12PUBLICATIONS
44CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 18, 2022
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma.

Andrew X Zhu, Farshid Dayyani, Chia-Jui Yen

|Apr 14, 2022
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.

Gontran Verset, Ivan Borbath, Mark Karwal

|Apr 14, 2022
EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.

Qibiao Wu, Yuanli Zhen, Lei Shi

|Apr 12, 2022
IFNα Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment.

Bo Hu, Mincheng Yu, Xiaolu Ma

|Mar 10, 2022
Neoadjuvant Approaches in Hepatocellular Carcinoma: There's No Time Like the Present.

Joseph W Franses, Andrew X Zhu

|Mar 05, 2022
Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials.

Josep M Llovet, Amit G Singal, Augusto Villanueva

Pageof 2

Frequent Collaborators

5 joint publications

Masatoshi Kudo

3 joint publications

Josep M Llovet

2 joint publications

Richard S Finn

2 joint publications

Peter R Galle